Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's

As reported by Barron's

Novartis pauses clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Barron's ↗

Market Samachar is a news aggregator. This article was originally published by Barron's. Tap the button above to read the full story on their site.

INDIAN Rupee holds firm at 94.97 as RBI intervenes with dollar sales Markets-Economic Times
INDIAN Global Market Today: Asian stocks advance as oil slips, yen in focus Markets-Economic Times
INDIAN MSCI to drop Swiggy from global indices on September 7 Markets-Economic Times
INDIAN Global bond slump looks painful, but its nothing like the 2022 rout Markets-Economic Times
COMPANIES Stocks in news: Swiggy, Adani Ports, IDFC First Bank, Hexaware Technologies and Sun Pharma Stocks-Markets-Economic Times
COMPANIES Zerodha unit gets nod for merchant banking Stocks-Markets-Economic Times
INDIAN IPO Boom: 10 issues cross 100x subscription in August, highest monthly tally since 2006 Markets-Economic Times
INDIAN Nifty stages recovery from lows; Can bulls push the index back above 24,000? mint - markets

Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's

More from Market Samachar